Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Immediate Tendonitis Relief Following Rotator Cuff Treatment
A minimally invasive procedure to treat tendonitis in the rotator cuff of the shoulder provides immediate symptom relief to the patient, according to a study published in the July issue of Radiology. The study found that ultrasound-guided nonsurgical therapy significantly reduces pain from calcific tendonitis of the rotator cuff and restores lasting mobility after treatment.
generic viagra online
Quinine Side Effects May Be Result Of Tryptophan Deficiency
Researchers have found that the anti-malarial drug quinine can block a cell"s ability to take up the essential amino acid tryptophan, a discovery that may explain many of the adverse side-effects associated with quinine. Once confirmed, these findings would suggest that dietary tryptophan supplements could be a simple and inexpensive way to improve the performance of this important drug.
News of the day
Washington's Basic Health Plan Raises Rates To Compensate For Budget Cuts
Washington state"s cash-strapped health insurance program, Basic Health Plan, "is resorting to steep premium increases to achieve what [its officials] were loath to do on their own - expel thousands of working-class people," the Seattle Times reports. Price hikes for the poorest plan members - who earn less than 125 percent of the poverty line - could double their premiums, while spikes are expected to be much higher for members with bigger incomes.
Health Insurance

Trinity Biotech Receives FDA Approval For Destiny Max In The USA

Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced the FDA approval and US launch of its high throughput haemostasis analyzer, the Destiny Max. Trinity has today obtained FDA approval of its Destiny Max analyzer and is now launching the instrument in the U.S. market with immediate effect. The target market for the instrument includes university hospitals, high throughput general hospitals, high volume commercial laboratories and reference laboratories. Key features of the Destiny Max include: -- being the only high throughput instrument on the worldwide market that allows simultaneous and automated measurement of mechanical and optical clot detection, chromogenic and immuno-turbidimetric assays; -- best in class graphical user interface and touch screen technology; -- the most reliable and novel cap piercing solution on the market. As part of its U.S. launch Trinity will be showcasing the Destiny Max at the ISTH Congress in Boston on 11-16 July, 2009 and at the AACC Clinical Lab Expo in Chicago on 21-23 July, 2009. Commenting on the approval Ronan O"Caoimh, CEO said, "I am delighted to announce FDA approval of the Destiny Max analyzer for the U.S. market. This follows the successful launch of Destiny Max in Europe and other international markets, following CE mark approval in December, 2008. The FDA approval and U.S. launch of Destiny Max represents a key strategic milestone for Trinity. This completes the roll out of Destiny Max in all major worldwide markets thus providing Trinity with access to the high throughput haemostasis market, estimated to be US$500 million per annum. This approval by the FDA significantly improves the marketability of the analyzer and represents a clear endorsement of Trinity"s ability to integrate hardware, software, reagents and consumables into a new state-of-the-art instrument platform that will exceed customer expectations. In the few short months since its international launch we have already enjoyed considerable success with the Destiny Max globally with sales in Japan, China, Italy, Ireland, the Netherlands, Germany, Australia, Turkey and the United Kingdom. Based on the market reaction we have received to date, I am more convinced than ever that we now have the best haemostasis instrument available on the market today. The combination of Destiny Max with our mid-throughput Destiny Plus and other instruments, in conjunction with our comprehensive reagent portfolio and strong service commitment means that Trinity is now in a leading position to offer a complete and best in class heamostasis product range to all customers in the market. This will undoubtedly act as a key driver for the growth of our haemostasis business going forward, which we expect will result in a significant increase in our market share." Trinity Biotech


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009